257 related articles for article (PubMed ID: 17253919)
41. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions.
Raad II; Hachem RY; Herbrecht R; Graybill JR; Hare R; Corcoran G; Kontoyiannis DP
Clin Infect Dis; 2006 May; 42(10):1398-403. PubMed ID: 16619151
[TBL] [Abstract][Full Text] [Related]
42. Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections.
Groll AH; Walsh TJ
Mycoses; 2006; 49 Suppl 1():7-16. PubMed ID: 16961576
[TBL] [Abstract][Full Text] [Related]
43. Posaconazole in intensive care patients I: invasive fungal infections in surgical intensive care and case presentation.
Störzinger D; Lichtenstern C; Swoboda S; Weigand MA; Hoppe-Tichy T
Mycoses; 2008 Sep; 51 Suppl 2():52-7. PubMed ID: 18721332
[TBL] [Abstract][Full Text] [Related]
44. Successful nonoperative management of gastrointestinal mucormycosis: novel therapy for invasive disease.
Mezhir JJ; Mullane KM; Zarling J; Satoskar R; Pai RK; Roggin KK
Surg Infect (Larchmt); 2009 Oct; 10(5):447-51. PubMed ID: 19485785
[TBL] [Abstract][Full Text] [Related]
45. Mucormycosis in hematologic malignancies: an emerging fungal infection.
Nosari A; Oreste P; Montillo M; Carrafiello G; Draisci M; Muti G; Molteni A; Morra E
Haematologica; 2000 Oct; 85(10):1068-71. PubMed ID: 11025599
[TBL] [Abstract][Full Text] [Related]
46. Review of treatment of zygomycosis with posaconazole in a patient with acute myeloid leukemia.
Vazquez JA
Clin Adv Hematol Oncol; 2005 Oct; 3(10):777-8. PubMed ID: 16258488
[No Abstract] [Full Text] [Related]
47. Mucormycosis peritonitis: more than 2 years of disease-free follow-up after posaconazole salvage therapy after failure of liposomal amphotericin B.
Sedlacek M; Cotter JG; Suriawinata AA; Kaneko TM; Zuckerman RA; Parsonnet J; Block CA
Am J Kidney Dis; 2008 Feb; 51(2):302-6. PubMed ID: 18215708
[TBL] [Abstract][Full Text] [Related]
48. Failure of voriconazole to cure disseminated zygomycosis in an immunocompromised child.
Ritz N; Ammann RA; Aebischer CC; Gugger M; Jaton K; Schmid RA; Aebi C
Eur J Pediatr; 2005 Apr; 164(4):231-5. PubMed ID: 15633048
[TBL] [Abstract][Full Text] [Related]
49. Treatment of zygomycosis with posaconazole in a patient with acute myeloid leukemia.
Leather HL; Correll TA; Meyer CL; Schmalfuss IM; Wingard JR
Clin Adv Hematol Oncol; 2005 Oct; 3(10):773-7. PubMed ID: 16258487
[No Abstract] [Full Text] [Related]
50. An increasing trend of cutaneous zygomycosis caused by Mycocladus corymbifer (formerly Absidia corymbifera): report of two cases and review of primary cutaneous Mycocladus infections.
Almaslamani M; Taj-Aldeen SJ; Garcia-Hermoso D; Dannaoui E; Alsoub H; Alkhal A
Med Mycol; 2009; 47(5):532-8. PubMed ID: 19184768
[TBL] [Abstract][Full Text] [Related]
51. [Pulmonary zygomycosis--a rare angioinvasive fungal infection].
Lewejohann J; Muhl E; Birth M; Kujath P; Bruch HP
Mycoses; 2005; 48 Suppl 1():99-107. PubMed ID: 15826297
[TBL] [Abstract][Full Text] [Related]
52. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007.
Skiada A; Pagano L; Groll A; Zimmerli S; Dupont B; Lagrou K; Lass-Florl C; Bouza E; Klimko N; Gaustad P; Richardson M; Hamal P; Akova M; Meis JF; Rodriguez-Tudela JL; Roilides E; Mitrousia-Ziouva A; Petrikkos G;
Clin Microbiol Infect; 2011 Dec; 17(12):1859-67. PubMed ID: 21199154
[TBL] [Abstract][Full Text] [Related]
53. Salvage therapy of refractory chronic disseminated candidiasis in a patient with acute myeloid leukaemia and secondary prophylaxis during allogeneic stem cell transplantation.
Vehreschild JJ; Krüger K; Kurzai O; Wickenhauser C; Behringer K; Töx U; Cornely OA
Mycoses; 2006; 49 Suppl 1():42-7. PubMed ID: 16961582
[TBL] [Abstract][Full Text] [Related]
54. Salvage treatment of histoplasmosis with posaconazole.
Restrepo A; Tobón A; Clark B; Graham DR; Corcoran G; Bradsher RW; Goldman M; Pankey G; Moore T; Negroni R; Graybill JR
J Infect; 2007 Apr; 54(4):319-27. PubMed ID: 16824608
[TBL] [Abstract][Full Text] [Related]
55. Clinical efficacy of new antifungal agents.
Kauffman CA
Curr Opin Microbiol; 2006 Oct; 9(5):483-8. PubMed ID: 16904366
[TBL] [Abstract][Full Text] [Related]
56. Successful treatment of Cryptococcal meningitis with a combination of liposomal amphotericin B, flucytosine and posaconazole: two case reports.
Esposito V; Viglietti R; Gargiulo M; Parrella R; Onofrio M; Sangiovanni V; Ambrosino D; Chirianni A
In Vivo; 2009; 23(3):465-8. PubMed ID: 19454515
[TBL] [Abstract][Full Text] [Related]
57. Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections.
Herbrecht R
Int J Clin Pract; 2004 Jun; 58(6):612-24. PubMed ID: 15311563
[TBL] [Abstract][Full Text] [Related]
58. Breakthrough zygomycosis on posaconazole prophylaxis after allogeneic stem cell transplantation.
Mousset S; Bug G; Heinz WJ; Tintelnot K; Rickerts V
Transpl Infect Dis; 2010 Jun; 12(3):261-4. PubMed ID: 19954497
[TBL] [Abstract][Full Text] [Related]
59. Activity of posaconazole in treatment of experimental disseminated zygomycosis.
Dannaoui E; Meis JF; Loebenberg D; Verweij PE
Antimicrob Agents Chemother; 2003 Nov; 47(11):3647-50. PubMed ID: 14576138
[TBL] [Abstract][Full Text] [Related]
60. Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis.
Lamaris GA; Ben-Ami R; Lewis RE; Chamilos G; Samonis G; Kontoyiannis DP
J Infect Dis; 2009 May; 199(9):1399-406. PubMed ID: 19358672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
